Stronger warnings about the risk of diabetic ketoacidosis with sodium glucose co-transporter 2 (SGLT2) inhibitors have been announced by the Therapeutic Goods Administration (TGA) . The regulator says it is working with manufacturers to update product information for products containing dapagliflozin and empagliflozin relating to the risk of DKA, particularly in the perioperative period. Warnings ...
TGA strengthens DKA warnings for SGLT2 inhibitors
By Michael Woodhead
19 Jul 2018